News | November 20, 2023
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
